The company previously focused on developing therapies including vurolenatide for short bowel syndrome and GIP antagonist NM-136 for obesity. Its pipeline-focused business model and clinical-stage status made it dependent on successful development milestones and funding.
The company has ceased operations, indicating failed commercialization efforts, likely capital constraints, and inability to advance its clinical pipeline. Stock price has declined significantly, reaching penny stock status with delisting concerns.
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.
Open report →